Menu
Innovation Observatory > Reports > Drugs > PLX-PAD for Critical Limb Ischaemia (with minor tissue loss) in Patients Unsuitable for Revascularisation

< Back

PLX-PAD for Critical Limb Ischaemia (with minor tissue loss) in Patients Unsuitable for Revascularisation

Drugs

Cardiovascular Disease and Vascular Surgery

February 2018


Critical Limb Ischaemia (CLI) is a cardiovascular condition resulting in the deterioration of blood vessels that supply the muscles in the limb. In CLI, blockages within the arteries restrict the flow of blood to affected limbs – typically the lower extremities. Pain in the feet, toes, and/or legs ensues and further complications may include ulcers and gangrenous non-healing wounds. Through surgery, blood circulation may be restored to the affected limb (revascularisation). However, in instances where this is not possible, amputation may be the only option to reduce pain and/or the risk of serious infection.
PLX-PAD is a type of cell therapy derived from the human placenta and works by stimulating the body’s own regenerative mechanisms in healing damaged tissues. PLX-PAD responds to chemical distress signals from tissues that have been damaged by the restriction of blood flow, improving blood and oxygen supply, and promoting healing. PLX-PAD is administered by injection to the muscles of the limb(s). If approved, it may offer CLI patients who are unsuitable for surgical management a minimally invasive alternative to reduce instances of amputation and improve overall quality of life.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Download Full Article



Load More Related Posts
Get Alerts